https://engagerbio.com/news-publications-engager-bio/ 2026-09-14T12:38:10+00:00 https://engagerbio.com/enhancing-immune-cell-engager-activity-with-lenalidomide/ 2026-08-31T15:05:49+00:00 https://engagerbio.com/121-2/ 2026-08-31T15:09:09+00:00 https://engagerbio.com/cd1d-directed-single-domain-antibodies-and-nkt-cell-activation/ 2026-09-14T12:34:10+00:00 https://engagerbio.com/targeting-cd40-biology-in-b-cell-malignancies/ 2026-09-14T12:34:33+00:00 https://engagerbio.com/the-promise-of-%ce%b3%ce%b4-t-cells-in-cancer-immunotherapy/ 2026-09-14T12:34:55+00:00 https://engagerbio.com/recruiting-nkt-and-v%ce%b39v%ce%b42-t-cells-against-blood-cancers/ 2026-09-14T12:35:32+00:00 https://engagerbio.com/clinical-development-of-psma-directed-%ce%b3%ce%b4-t-cell-engagement/ 2026-09-14T12:35:58+00:00 https://engagerbio.com/early-clinical-observations-for-cd1d-directed-%ce%b3%ce%b4-t-cell-engagement/ 2026-09-14T12:36:26+00:00 https://engagerbio.com/egfr-directed-%ce%b3%ce%b4-t-cell-engagement/ 2026-09-14T12:36:44+00:00 https://engagerbio.com/expanding-v%ce%b39v%ce%b42-t-cells-while-engaging-tumors/ 2026-09-14T12:37:01+00:00 https://engagerbio.com/targeting-prostate-cancer-with-psma-v%ce%b42-engagement/ 2026-09-14T12:37:23+00:00 https://engagerbio.com/combining-tumor-targeting-with-checkpoint-biology/ 2026-09-14T12:38:10+00:00